Item 8.01 Other Events.

On December 19, 2012, ADVENTRX Pharmaceuticals, Inc. issued a press release announcing updates with regard to the initiation of its planned phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.

---

Top of the Form